|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-11-3
|
|
pubmed:abstractText |
Gefitinib inhibits epidermal growth factor receptor (EGFR) signalling, but may also act by non-EGFR dependent mechanisms. We have investigated the activity of gefitinib in haematological tumour cells, in particular acute myeloblastic leukaemia (AML).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1600-0609
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
81
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
344-53
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18637032-Adult,
pubmed-meshheading:18637032-Aged,
pubmed-meshheading:18637032-Antineoplastic Agents,
pubmed-meshheading:18637032-Apoptosis,
pubmed-meshheading:18637032-Caspase 3,
pubmed-meshheading:18637032-Drug Screening Assays, Antitumor,
pubmed-meshheading:18637032-Female,
pubmed-meshheading:18637032-Humans,
pubmed-meshheading:18637032-Immunochemistry,
pubmed-meshheading:18637032-Leukemia, Myeloid, Acute,
pubmed-meshheading:18637032-Male,
pubmed-meshheading:18637032-Middle Aged,
pubmed-meshheading:18637032-Quinazolines,
pubmed-meshheading:18637032-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18637032-Tumor Cells, Cultured
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
